血清INTS6P1作为肝细胞癌疾病筛查新型标志物的可行性研究

The feasibility study on serum INTS6P1 as an novel marker for screening hepatocellular carcinoma

目的探讨血清中整合因子复合体亚基6假基因1(INTS6P1)作为肝细胞癌患者疾病筛查新型标志物的可行性。方法采用Northern杂交方法检测33例肝细胞癌患者肿瘤组织及临近肺肿瘤组织中INTS6P1的表达情况,通过细胞试验检测INTS6P1在细胞培养上清和胞内表达情况,最后检测INTS6P1在100例患者体内的表达情况。结果与临床非肿瘤组织相比,33例肝细胞癌患者肿瘤组织中的INTS6P1表达量显著降低(P=0.0066)。血清检测结果表明,肝细胞癌患者血清中INTS6P1表达水平显著低于非肝细胞癌患者(P<0.01)。此外,曲线下面积-ROC曲线分析表明,血清-AFP含量低于20 ng/ml时INTS6P1可以作为肝细胞癌患者疾病筛查的诊断标志物(P<0.05)。结论血清INTS6P1可以作为肝细胞癌疾病筛查新型标志物,将该标志物纳入检测能提高肝细胞癌临床诊断的准确率。

Objective To investigate the feasibility of pseudogene integrator complex subunit 6 pseudogene 1（ INTS6P1） in serum as an novel marker to screen hepatocellular carcinoma（ HCC）. Methods The expression levels of INTS6P1 were detected by Northern hybridization method in 33 cases of hepatocellular carcinoma tissues and adjacent normal liver tissues. Moreover the expressions of INTS6P1 in supernatant of cell culture were measured by means of cell culture in vitro,besides,the expression levels of INTS6P1 were detected in 100 patients with HCC in vivo. Results As compared with those in adjacent normal liver tissues,the expression levels of INTS6P1 in 33 cases of hepatocellular carcinoma tissues were significantly decreased（ P〈0. 01）. The expression levels of INTS6P1 in serum of patients with HCC were significantly lower than those of patients with non-HCC（ P〈0. 01）. In addition,the AUC-ROC curve analysis showed that when the serum levels of AFP were lower than 20 ng / ml,INTS6P1 could be regarded as a diagnostic marker for screening hepatocellular carcinoma（ P〈0. 05）. Conclusion The serum INTS6P1 can be regarded as an novel marker for screening hepatocellular carcinoma,moreover,the detection of serum INTS6P1 can increase the accuracy of clinical diagnosis of HCC.